ECX ECX
Company Profile ↓Company Overview
ECX (ECX) is a publicly traded company listed on with a market capitalization of $443.55M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 23.4%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 31.1%.
Revenue has grown at a 18.0% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $847.86M (+9.9% YoY); net profit $-66.04M.
- Trailing 12 Months Year-on-year growth — revenue +9.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 18.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 17.98% |
| 1 Year: | 9.89% |
Stock Price Performance
| 1 Year: | -28.40% |
| 6 Months: | -37.30% |
| 3 Months: | +4.50% |
| 1 Month: | -4.92% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)54.81 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 23.4%.
- Healthy ROCE of 31.1%.
- Compounding revenue at 18.0% over 5 years.
CONS
- Trading 56.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 167.70M | 154.99M | 219.90M | 304.66M | 131.50M |
| Cost of Revenue | 134.50M | 138.38M | 172.30M | 241.00M | 103.30M |
| Gross Profit | 33.20M | 16.62M | 47.60M | 63.66M | 28.20M |
| Operating Expenses | 57.90M | 53.89M | 44.30M | 51.84M | 41.20M |
| Operating Income | -24.70M | -37.28M | 3.30M | 11.83M | -13.00M |
| EBITDA | -22.20M | -38.21M | 4.50M | 11.88M | -200.00K |
| Interest Expense | 4.70M | 5.52M | 3.70M | 9.87M | 9.70M |
| Pretax Income | -26.90M | -43.73M | 800.00K | 2.00M | -9.90M |
| Tax Provision | 300.00K | 1.80M | -100.00K | -756.00K | 1.10M |
| Net Income | -26.00M | -43.16M | 400.00K | 2.56M | -10.60M |
| Diluted EPS | -0.08 | -0.13 | 0.00 | -0.02 | -0.03 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 516.28M | 662.23M | 771.53M | 847.86M |
| Cost of Revenue | - | 372.23M | 483.61M | 611.43M | 686.60M |
| Gross Profit | - | 144.06M | 178.62M | 160.10M | 161.26M |
| Operating Expenses | - | 374.47M | 307.72M | 280.26M | 211.24M |
| Operating Income | - | -230.42M | -129.11M | -120.16M | -49.97M |
| EBITDA | - | -205.38M | -115.59M | -92.57M | -19.53M |
| Interest Expense | - | 6.46M | 11.24M | 18.57M | 23.77M |
| Pretax Income | - | -228.73M | -144.42M | -137.54M | -67.69M |
| Tax Provision | - | 4.21M | -525.00K | 210.00K | 1.24M |
| Net Income | - | -226.71M | -133.31M | -129.76M | -66.04M |
| Diluted EPS | - | -1.15 | -0.39 | -0.38 | -0.39 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 685.73M | 607.63M | 514.34M | 662.41M |
| Current Assets | - | 558.51M | 469.53M | 386.13M | 483.18M |
| Cash & Equivalents | - | 124.72M | 80.66M | 44.25M | 87.12M |
| Inventory | - | 26.46M | 22.68M | 31.86M | 62.34M |
| Receivables | - | 181.69M | 262.18M | 217.39M | 200.34M |
| Total Liabilities | - | 690.72M | 724.95M | 752.05M | 945.88M |
| Current Liabilities | - | 569.25M | 599.87M | 698.65M | 823.00M |
| Long Term Debt | - | 63.76M | 64.29M | - | 65.87M |
| Total Debt | - | 228.74M | 255.11M | 291.37M | 455.34M |
| Total Equity | - | -28.47M | -129.59M | -239.67M | -282.66M |
| Shares Outstanding | - | 337.40M | 337.95M | 340.13M | 382.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -66.87M | -172.44M | -59.98M | -94.39M |
| Investing Cash Flow | - | -45.37M | 87.27M | -8.12M | -70.48M |
| Financing Cash Flow | - | 95.34M | 40.62M | 36.35M | 203.86M |
| Capital Expenditure | - | -22.80M | -8.88M | -15.91M | -12.17M |
| Free Cash Flow | - | -89.66M | -181.32M | -75.89M | -106.56M |
| Net Change in Cash | - | -16.90M | -44.56M | -31.75M | 38.99M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 27.9% | 27.0% | 20.8% | 19.0% |
| Operating Margin % | - | -44.6% | -19.5% | -15.6% | -5.9% |
| Net Margin % | - | -43.9% | -20.1% | -16.8% | -7.8% |
| ROE % | - | 796.4% | 102.9% | 54.1% | 23.4% |
| ROCE % | - | -197.8% | -1,664.1% | 65.2% | 31.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ECX
ECARX management presentation in New York will be webcast Aug. 12 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPTHA3d3EwSGMwbm9KaDh3LTR0YklpRUlSOE1IUG5tZHVtQ3R5dDRNTU1BdmQ0OHZrbWhGM0kyM2hOVVkzZVFPdHlqelZDU2xoRmRaeDU1UVk4ZmFXbGc0am9yYlVvcGNOeExkdDFFeW1tdlY5WFh3RWEyOGtfclNCeE1QMlgxOUgyVVU4ME…
Epigenomics AG Revenue Breakdown – FWB:ECX - TradingView
<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE1PdEJ4MHgxTjk5ek9VOUd4X0dQV3lWODhISGhySjZ4eUdrRU1SUmVtUzlMUG1JVEx3Y0VEZVZpRnZBZlNGZEFFNkFWdkhTODNQZFp6b05GLThQRlV1Zl82TU1QNDZDeEZEYTh4aU5udnlJdw?oc=5" target="_blank">Epigenomics A…
ECX|Ecarx Holdings Inc.|Price:1.090| - TradingKey
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE1yQ3UtWmhLUHhYUHBuOGVhT2piMXJmTDNubzRXRC1iY1o3ZkZ3bXIzWnJRazJuVkJMVzl1SG4tUlMzb3dkY0cxbVRldTZBVk5Fa3ZvMjBTUk8?oc=5" target="_blank">ECX|Ecarx Holdings Inc.|Price:1.090|</a> &n…
ECARX Holdings (ECX) Committed Towards its Acquisitive Strategy - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPY25JZXlCYXhiWlFCQnNHaTVtckN5dkVzYTdxZENXTE1ITWNJRGxOaU9ubkNUV0FkR1hqOFFXSFRWclNJajlYOXBMZy0wdEFjbW1fVk1pQ3lpc3ZsamVMdnJmWUJaY2tadzRySUR3Q0JWM3ZyRHhIZHVNRXU3MXRNR3JVWVAyYndQcm9VRV…
SiEngine Unveils 5nm Car Chip With Native AI Language Model - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNNk1FaDFQM3JWM2h4UnA2TGREbUd5S0pJcENreDNHXzFyS1RyeWt5YmxMWFZ1YzI3Y0x6N1NlUDZaVW1lQ2NtYTV5OTJ6Vmp5UzJtRDRJVzhZcXFUT25XTFctdUdEMUVRUzBqQlJiUDJBY1V2VTNPWkd0ZTZrR1FHdURKMF9EUjVJNlVreU…
ECARX ($ECX) Releases Q1 2026 Earnings | ECX Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxQa1J5WkVBbDFOWTM3ak8tQjZQRi11NWdwWElaLW53aTlNbE1uOHg0WG9IM05iUTB2ZXVrRDl1WlNCSlVFaXNUN0k4SXRoRjYwQ2J4SHBOYWdBM1pvYXVzWDEwYzhuVmo4dWdab3VIcjk1Mll1dEcyUFRSa2lGcVc2SExBRQ?oc=5" targe…
ECX — Frequently Asked Questions
What is the current share price of ECX?
As of 2026-08-05 17:25 PDT, ECX trades at $1.16 on NASDAQ/NYSE. Its 52-week range is $0.88 to $2.64.
What is the market capitalisation of ECX?
ECX has a market capitalisation of $443.55M on NASDAQ/NYSE.
What is the P/E ratio of ECX?
ECX trades at a trailing price-to-earnings (P/E) ratio of -2.97. Its price-to-book (P/B) ratio is -1.57.
What is the return on equity (ROE) of ECX?
ECX has a return on equity (ROE) of 23.36%. Its return on capital employed (ROCE) is 31.12%.
Is ECX a good stock to buy?
This page provides a data-driven analysis of ECX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.